NewLimit aims to develop novel anti-aging therapeutics
NewLimit, a South San Francisco-based company, is focused on discovering a new class of drugs that target aging. The company has raised $682 million from investors including Kleiner Perkins and Eli Lilly Ventures. Its co-founders include Jacob Kimmel and Brian Armstrong.
NewLimit operates out of South San Francisco with a stated mission to create an entirely new category of pharmaceutical treatments aimed at the biological processes of aging itself, rather than addressing individual age-related diseases. The company's approach represents a significant bet on the emerging field of longevity medicine, which seeks to intervene at the cellular level to extend healthy lifespan.
The venture has attracted substantial financial backing, securing $682 million from prominent investors, including venture capital firm Kleiner Perkins and Eli Lilly Ventures, the investment arm of the major pharmaceutical company. The company was co-founded by Jacob Kimmel and Brian Armstrong, bringing together expertise in biology and technology to pursue this ambitious research agenda.
If successful, NewLimit's therapeutics could fundamentally shift how society approaches aging, potentially extending the period of healthy, active life for millions of older adults. This may reduce long-term healthcare costs and caregiver burden, while also raising complex questions about retirement, insurance, and equitable access to such treatments. The substantial investment from major pharmaceutical players suggests the field is gaining mainstream credibility, though the timeline for any actual therapies remains uncertain.